Rapport Secures $20M Upfront, Up to $308M Milestones in China RAP-219 Partnership
Summary
Rapport Therapeutics has announced a strategic collaboration with Tenacia Biotechnology for the development and commercialization of its key drug candidate, RAP-219, in Greater China. Under the terms, Rapport will receive an upfront payment of $20 million and is eligible for up to $308 million in potential development and commercial milestones, along with tiered royalties on net sales. This partnership provides significant non-dilutive capital, strengthening Rapport's financial position and allowing continued investment in other programs. Critically, it leverages Tenacia's regional expertise to accelerate the global Phase 3 development of RAP-219 for focal onset seizures, with clinical trial sites in China. This deal expands the market reach for RAP-219 and de-risks its development pathway, representing a material positive for the company's long-term prospects.
At the time of this announcement, RAPP was trading at $30.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.40 to $42.27. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.